On December 23, Gelonghui reported that Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. (hereinafter referred to as "Qingyutang"), recently received the "Drug Registration Application Termination Notice" issued by the National Medical Products Administration.

The indication for acetylcysteine injection is for the treatment of acetaminophen overdose. Due to market changes and other factors and after careful study, in combination with the company's research and development strategy, the company has decided to actively withdraw this registration application.